Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Buy” from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.00.

Several equities analysts have recently weighed in on PYXS shares. Stifel Nicolaus started coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Friday, August 16th.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the stock. StemPoint Capital LP bought a new stake in shares of Pyxis Oncology during the 1st quarter worth approximately $7,643,000. Ikarian Capital LLC bought a new position in Pyxis Oncology in the first quarter valued at about $7,082,000. Vanguard Group Inc. boosted its stake in shares of Pyxis Oncology by 7.3% during the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after purchasing an additional 94,740 shares in the last quarter. Millennium Management LLC increased its stake in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after buying an additional 743,499 shares during the period. Finally, Blue Owl Capital Holdings LP bought a new position in Pyxis Oncology in the 2nd quarter valued at approximately $3,462,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Trading Down 2.7 %

PYXS stock opened at $3.62 on Friday. The stock has a market cap of $215.10 million, a PE ratio of -2.66 and a beta of 1.28. The stock has a 50-day moving average price of $3.61 and a two-hundred day moving average price of $3.91. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. On average, analysts forecast that Pyxis Oncology will post -1.07 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.